Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ilaris Safety Data Inadequate For Gout Indication, FDA Panel Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Arthritis Advisory Committee votes against approval of Novartis' biologic for treatment of gout attacks, citing the need for more data on long-term safety and retreatment, along with a narrower indication.
Advertisement

Related Content

Paladin’s Impavido Could Set A Price Tag For Priority Review Vouchers
Regeneron Likely Facing New Gout Study Following Arcalyst “Complete Response” Letter
Regeneron’s Arcalyst Gets Advisory Committee For Niche Gout Indication
Juvenile Arthritis Data For Novartis' Ilaris Also Supports Role In Gouty Arthritis
Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter
Ilaris Diabetes, Cardiovascular Trials Are Unethical, Public Citizen Says
Ilaris Gout Review Reflects Tougher FDA Approach To Biologic Dosing Safety
Novartis' Ilaris For Gout: FDA Questions Whether Symptom Relief Is Worth Risks
FDA Awards First-Ever Priority Review Voucher To Novartis For Coartem Approval
FDA Awards First-Ever Priority Review Voucher To Novartis For Coartem Approval

Topics

Advertisement
UsernamePublicRestriction

Register

PS072400

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel